• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当前实体器官移植受者疱疹病毒感染管理的观点。

Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients.

机构信息

Department of Internal Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.

Erasmus MC Transplant Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.

出版信息

Viruses. 2023 Jul 21;15(7):1595. doi: 10.3390/v15071595.

DOI:10.3390/v15071595
PMID:37515280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10383436/
Abstract

Solid organ transplant recipients (SOTRs) are at high risk of human herpesvirus (HHV)-related morbidity and mortality due to the use of immunosuppressive therapy. We aim to increase awareness and understanding of HHV disease burden in SOTRs by providing an overview of current prevention and management strategies as described in the literature and guidelines. We discuss challenges in both prevention and treatment as well as future perspectives.

摘要

实体器官移植受者(SOTR)由于使用免疫抑制疗法,存在发生人类疱疹病毒(HHV)相关发病率和死亡率的高风险。我们旨在通过概述文献和指南中描述的当前预防和管理策略,提高对 SOTR 中 HHV 疾病负担的认识和理解。我们讨论了预防和治疗方面的挑战以及未来的展望。

相似文献

1
Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients.当前实体器官移植受者疱疹病毒感染管理的观点。
Viruses. 2023 Jul 21;15(7):1595. doi: 10.3390/v15071595.
2
Human herpesviruses 6 and 7 in solid organ transplant recipients.实体器官移植受者中的人类疱疹病毒6型和7型
Clin Infect Dis. 2001 May 1;32(9):1357-60. doi: 10.1086/320000. Epub 2001 Apr 10.
3
HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients.实体器官移植受者中的人疱疹病毒6型、人疱疹病毒7型和人疱疹病毒8型
Am J Transplant. 2009 Dec;9 Suppl 4:S97-100. doi: 10.1111/j.1600-6143.2009.02899_1.x.
4
HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients.实体器官移植受者中的人疱疹病毒6型、人疱疹病毒7型和人疱疹病毒8型。
Am J Transplant. 2009 Dec;9 Suppl 4:S100-3. doi: 10.1111/j.1600-6143.2009.02899_2.x.
5
Human herpesviruses 6, 7 and 8 in solid organ transplant recipients.人类疱疹病毒 6、7 和 8 与实体器官移植受者。
Am J Transplant. 2013 Feb;13 Suppl 3:67-77; quiz 77-8. doi: 10.1111/ajt.12008.
6
Human herpesvirus 6, 7, and 8 in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.人类疱疹病毒 6、7 和 8 与实体器官移植:美国移植感染病学会实践社区指南。
Clin Transplant. 2019 Sep;33(9):e13518. doi: 10.1111/ctr.13518. Epub 2019 Apr 4.
7
Infections due to human herpesvirus 6 in solid organ transplant recipients.实体器官移植受者中由人类疱疹病毒 6 引起的感染。
Curr Opin Organ Transplant. 2010 Dec;15(6):671-5. doi: 10.1097/MOT.0b013e3283404325.
8
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.影响器官移植受者皮肤的病毒感染:流行病学与当前管理策略
Am J Clin Dermatol. 2006;7(1):13-29. doi: 10.2165/00128071-200607010-00003.
9
Significance of human herpesviruses to transplant recipients.人类疱疹病毒对移植受者的意义。
Curr Opin Infect Dis. 2003 Dec;16(6):601-6. doi: 10.1097/00001432-200312000-00014.
10
Human herpesviruses-6, -7 and -8 in organ transplant recipients.器官移植受者中的人类疱疹病毒6型、7型和8型
Clin Microbiol Infect. 2000 Sep;6(9):453-9. doi: 10.1046/j.1469-0691.2000.00129.x.

引用本文的文献

1
Management of Antiretroviral Therapy and Opportunistic Infections in People Living with HIV Undergoing Hematopoietic Stem Cell Transplant in British Columbia.不列颠哥伦比亚省接受造血干细胞移植的艾滋病毒感染者的抗逆转录病毒治疗和机会性感染管理
J Assoc Med Microbiol Infect Dis Can. 2024 Dec 19;9(4):249-273. doi: 10.3138/jammi-2024-0013. eCollection 2024 Dec.
2
Late-Onset HSV-2 Encephalitis in a Kidney Transplant Recipient: A Rare Case Report.肾移植受者中的迟发性单纯疱疹病毒2型脑炎:一例罕见病例报告
Life (Basel). 2025 Jan 22;15(2):152. doi: 10.3390/life15020152.
3
Cutaneous perianal herpes simplex virus infection mimicking condylomata acuminata in a renal transplant recipient: A case report and literature review.肾移植受者中表现为尖锐湿疣的肛周皮肤单纯疱疹病毒感染:一例报告及文献复习
Clin Case Rep. 2024 Sep 10;12(9):e9428. doi: 10.1002/ccr3.9428. eCollection 2024 Sep.
4
Causality between herpes virus infections and allograft dysfunction after tissue and organ transplantation: a two-sample bidirectional Mendelian randomization study.组织和器官移植后疱疹病毒感染与移植物功能障碍之间的因果关系:两样本双向孟德尔随机化研究。
Front Immunol. 2024 Aug 14;15:1411771. doi: 10.3389/fimmu.2024.1411771. eCollection 2024.
5
CRISPR-Cas Systems and Genome Editing: Beginning the Era of CRISPR/Cas Therapies for Humans.CRISPR-Cas 系统与基因组编辑:开启人类 CRISPR/Cas 疗法新时代。
Int J Mol Sci. 2024 May 13;25(10):5292. doi: 10.3390/ijms25105292.

本文引用的文献

1
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.来特莫韦与缬更昔洛韦预防高危肾移植受者巨细胞病毒感染:一项随机临床试验。
JAMA. 2023 Jul 3;330(1):33-42. doi: 10.1001/jama.2023.9106.
2
Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies.移植后淋巴组织增生性疾病:治疗和新疗法的最新进展。
Br J Haematol. 2023 May;201(3):383-395. doi: 10.1111/bjh.18763. Epub 2023 Mar 22.
3
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients.更昔洛韦群体药代动力学和药效学分析在优化肾移植受者巨细胞病毒感染的 preemptive 治疗中的应用。
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0166522. doi: 10.1128/aac.01665-22. Epub 2023 Feb 23.
4
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.在未对两到三剂 mRNA 疫苗(RECOVAC)产生应答的肾移植受者中提高 COVID-19 疫苗免疫原性的替代策略:一项随机临床试验。
Lancet Infect Dis. 2023 Mar;23(3):307-319. doi: 10.1016/S1473-3099(22)00650-8. Epub 2022 Oct 27.
5
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination.佐剂重组带状疱疹疫苗对带状疱疹的长期保护作用:初次接种后长达10年的中期疗效、免疫原性和安全性结果
Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485. doi: 10.1093/ofid/ofac485. eCollection 2022 Oct.
6
Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021.移植环境中的巨细胞病毒:我们现在在哪里,下一步会发生什么?来自 2021 年国际巨细胞病毒研讨会的报告。
Transpl Infect Dis. 2022 Dec;24(6):e13977. doi: 10.1111/tid.13977. Epub 2022 Nov 11.
7
Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.来特莫韦用于高危心脏移植受者的巨细胞病毒预防
Clin Transplant. 2022 Dec;36(12):e14808. doi: 10.1111/ctr.14808. Epub 2022 Oct 26.
8
Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation.增强 VZV 特异性记忆 B 和 T 细胞应答以预防肾移植后带状疱疹。
Front Immunol. 2022 Jul 22;13:927734. doi: 10.3389/fimmu.2022.927734. eCollection 2022.
9
Adjuvanted recombinant zoster vaccine in solid organ transplant and hematopoietic stem-cell transplant recipients.佐剂重组带状疱疹疫苗在实体器官移植和造血干细胞移植受者中的应用。
Curr Opin Infect Dis. 2022 Aug 1;35(4):312-320. doi: 10.1097/QCO.0000000000000845. Epub 2022 Jul 5.
10
Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium.移植受者的巨细胞病毒感染:我们武器库中的新批准添加物。
Clin Microbiol Infect. 2023 Jan;29(1):44-50. doi: 10.1016/j.cmi.2022.07.001. Epub 2022 Jul 15.